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Kinase inhibitorsCK2 is a serine/threonine protein kinase, which is so important for many aspects of cellular regulation that life
without CK2 is impossible. Here, we analysed CK2 during adipogenic differentiation of human mesenchymal
stem cells (hMSCs). With progress of the differentiation CK2 protein level and the kinase activity decreased.
Whereas CK2α remained in the nucleus during differentiation, the localization of CK2β showed a dynamic shuttling
in the course of differentiation. Over the last years a large number of inhibitors of CK2 kinase activitywere generated
with the idea to use them in cancer therapy. Our results show that twohighly speciﬁc inhibitors of CK2, CX-4945 and
quinalizarin, reduced its kinase activity in proliferating hMSCwith a similar efﬁciency. CK2 inhibition by quinalizarin
resulted in nearly complete inhibition of differentiation whereas, in the presence of CX-4945, differentiation
proceeded similar to the controls. In this case, differentiation was accompanied by the loss of CX-4945 inhibitory
function. By analysing the subcellular localization of PPARγ2, we found a shift from a nuclear localization at the
beginning of differentiation to a more cytoplasmic localization in the presence of quinalizarin. Our data further
show for the ﬁrst time that a certain level of CK2 kinase activity is required for adipogenic stem cell differentiation
and that inhibition of CK2 resulted in an altered localization of PPARγ2, an early regulator of differentiation.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Adipogenesis denotes the development of differentiated adipocytes
from multipotent mesenchymal precursor cells. The multipotent
mesenchymal stem cells (MSCs) are adult stem cells with a ﬁbroblastoid
shape and a high ability for self-renewal [11]. They can be isolated –
among others – from adipose tissue and bonemarrow. They are charac-
terized by different surface markers, i.e. they lack the haematopoietic
markers CD23 and CD45, but express high levels of CD29, CD44, CD73,
CD90, CD105 and CD106 [49]. By diverse extracellular signals MSCs
are prompted to differentiate into several lineages like osteoblasts,
chondrocytes, myoblasts or adipocytes in vivo and in vitro [60]. Many
ﬁndings concerning the events during differentiation of stem cells
were obtained from model cell lines like the pluripotent stem cell line
C3H10T/1/2 [51] or the preadipocyte cell line 3T3-L1 [20,21] which
have been proven reliable models for the processes occurring during
differentiation. During differentiation hMSCs undergo deﬁned phases
which begin with mitotic clonal expansion, commitment to a certainochemie undMolekularbiologie,
ermany.
y to this work.lineage, lineage progression, terminal differentiation, and ﬁnally
maturation [6,7]. Lineage determination seems to be regulated by a
large network of extracellular signalling factors which exert an impact
on the promoters of lineage speciﬁc transcription factors. Balancing
these different signalling molecules and pathways determines the fate
of the MSC ([66] and literature therein). In the late phase of adipogenic
differentiation adipocyte speciﬁc proteins like perilipin, lipoprotein lipase,
glycerol phosphate dehydrogenase, leptin and adiponectin are expressed
which support the characteristics of an adipocyte phenotype [44].
The activity of several signalling molecules and transcription factors
during differentiation is controlled by phosphorylation [27,33,68]. Also
the commitment of human mesenchymal stem cells to an osteogenic
or adipogenic lineage is regulated by protein kinases [26,28,34]. One
of the kinases whichmight also be implied in the regulation of differen-
tiation is protein kinase CK2.
CK2 is one of the most pleiotropic protein kinases with hundreds of
substrates already known [37,52]. It is an ubiquitous heterotetrameric
serine/threonine kinase, consisting of two catalytic α- or α′-subunits
and two non-catalytic β-subunits, which is deeply implicated in a
multitude of cellular processes including embryonal development
and differentiation. A lack of the catalytic α- or the regulatory β-subunit
is not compatible with life [5,35].
During early embryogenesis of themouse, the catalytic aswell as the
non-catalytic subunits of CK2 are particularly expressed in neuronal
tissues, in later stages CK2 is found everywhere in the body [40]. Similar
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Caenorhabditis elegans [23]. The enhanced expression goes along with
an enhancement of the CK2 activity which reaches a maximum at
day 11 during mouse embryogenesis and is then subsequently
down-regulated [55]. Changes in activity depending on the embryonic
stage were conﬁrmed for rat and for C. elegans [22,46].
CK2β is discussed as a positive regulator for the proliferation of
neuronal progenitor cells and their multipotency [75]. Knocking out
the gene for the regulatory β-subunit in mice leads to a diminished
cell proliferation and the development of the murine embryos stops at
the blastocyst stage with the resorption of the embryo. CK2β−/−
blastocysts are not able to generate an inner cellmass [5].Mouse embryos
with a lack of CK2β in neuronal stem cells show a disturbed cell
proliferation and severe defects in brain development [24].
When knocking out the α-subunit of CK2, mouse embryos die
during embryogenesis and exhibit structural injuries in the heart and
neural tube [12,35]. The lack of the catalytic α′-subunit is compatible
with life; however, it is detrimental for spermatogenesis and male
α′-knock-out mice are infertile [14,73].
In a number of different genetic experiments it has been demon-
strated that mice with combined loss of CK2α and CK2α′ are viable
as long as one of the two CK2α alleles is present [31]. Furthermore,
these experiments have demonstrated that a combined loss of one
CK2α allele or both CK2α′ alleles leads to abnormalities in growth and
development of the offspring. In particular, CK2α+/− CK2α′−/− mice
differ in weight but not in size compared to their wild-type litter mates.
In fact, knock-out mice were found to have about 50% of the body fat
compared to mice of other genotypes. There are some observations
about a distinct role of CK2 upon signalling during differentiation in
several stem cell models for haematopoietic [8,13,65], osteogenic [3,4]
or neuronal differentiation [19,70]. In these publications there are exam-
ples for a positive as well as a negative role for CK2 in differentiation.
There are only few indications that CK2 might be employed in the
differentiation of established stem cell or preadipocyte lines to adipocytes
[41,72]. In the preadipocyte line 3T3-L1 CK2 is necessary for the early
stages of differentiation. Upon inhibition of CK2 preadipocytes fail to
differentiate into mature adipocytes [72]. In later phases the expression
as well as the activity of CK2 has to be down-regulated to enable a
successful differentiation.
Over the last 8 years thedevelopment of a great number of inhibitors
of the kinase activity of CK2 with an increasing speciﬁcity has provided
new tools for studying the role of CK2 for many biological processes
[10,50,53]. Here we used two highly speciﬁc CK2 inhibitors – CX-
4945 [47] and quinalizarin [9] – for the investigation of the fate of
human mesenchymal stem cells (hMSCs) with respect to adipogenic
differentiation.
2. Material and methods
2.1. Isolation of human mesenchymal stem cells
Human mesenchymal stem cells (hMSCs) were isolated from bone
marrow of the caput femoris from patients undergoing hip replacement
surgery. Brieﬂy, bone fragments were minced and isolated cells were
pooled in α-MEM. Mononuclear cells (MNC) were extracted by ﬁcoll
density gradient centrifugation at 350 ×g for 30 min. Collected cells
were seeded in complete medium (α-MEM, 15% foetal bovine serum
(FBS) and 100 U/ml penicillin and 100 μg/ml streptomycin) and cultured
in a humidiﬁed atmosphere and 5% CO2 at 37 °C. The medium was
changed twice a week. Before reaching conﬂuence, cells were harvested
with trypsin/EDTA and seeded at 1 × 103 cells/cm2 for further expansion.
Prior to their usage the stem cell potential of hMSC was veriﬁed by
the expression of cell surface markers CD29, CD44, CD73, CD90,
CD105, CD106 and HLA-ABC as well as absence of CD34, CD45,
CD133 and HLA-DR and their ability to differentiate adipogenically
and osteogenically.2.2. Cell cultivation, differentiation and treatment
Characterized hMSCs were cultivated in complete medium and kept
at a maximum conﬂuence of 70–80%. For adipogenic differentiation
cells were seeded into six-well plates or in 60 mm culture dishes at a
density of 1.5 × 104 cells/cm2. When cells reached conﬂuence the
culture medium was replaced by the differentiation mix (α-MEM, 10%
heat-inactivated FCS, 500 μM isobutylmethylxanthine (IBMX), 100 nM
dexamethasone, 200 μM indomethacin and 100 ng/ml insulin)
(corresponds to day 0 of the differentiation). Differentiationmedium
was replaced twice a week.
The CK2 inhibitors CX-4945 (Selleckchem, Munich, Germany) or
quinalizarin (1,2,5,8-tetrahydroxyanthraquinone) (Labotest OHG,
Niederschöna, Germany) were dissolved in dimethyl sulfoxide (DMSO)
to a 20 mM stock solution, which was used to treat the cells with a ﬁnal
concentration of 20 or 30 μM, unless otherwise stated. The inhibitors
were added with every change of the differentiation medium. The same
volume of the solvent DMSO was used in control experiments without
CK2 inhibitors.
2.3. Staining of lipid droplets in hMSC
After 3 weeks of differentiation cells were washed with PBS, ﬁxed in
3.7% formaldehyde in PBS for 15 min at room temperature and then
washed again. Cells were permeabilized with 0.2% Triton X-100, 5%
bovine serumalbumin in PBS for 15min on ice. Then, cells werewashed
twice and incubated with the lipid staining dye Bodipy® (493/503)
(Invitrogen, Karlsruhe, Germany) (50 μl/ coverslip, 30 μg Bodipy®/ml
PBS) for 1 h at room temperature in a humidiﬁed chamber in the dark.
To stain the nuclei, cells were incubated with 4′,6-diamidino-2-
phenylindole (DAPI) (50 μl, 5 ng/ml) at 37 °C for 15 min. Finally, cells
were washed again and analysed under a ﬂuorescence microscope
(excitation wave length: Bodipy®: 488 nm, DAPI: 340 nm).
Alternatively, lipids were visualized with OilRedO (Sigma Aldrich,
Munich, Germany). After removing the medium and washing with
PBS, cells were ﬁxed in 10% formaldehyde in PBS for 30 min at room
temperature and then washed twice with deionized H2O. Cells were
incubated for 3 min with 60% isopropanol. OilRedO was dissolved in
isopropanol (0.3 g/100 ml). A fresh 60% staining solution of OilRedO
was prepared with deionized H2O, incubated for 10 min at room
temperature and subsequently ﬁltered through a folded ﬁlter (3MM,
Whatman, United Kingdom). Cells were incubated with the staining
solution for 5 min at room temperature. After incubation, the OilRedO
solution was removed and cells were washed three times with distilled
water. The staining of the lipid droplets was visualized by phase
contrast microscopy.
2.4. Immunoﬂuorescence analysis
For immunoﬂuorescence analysis hMSCs were seeded in 8 well
Permanox slides (Nalge Nunc International Corp., Naperville, USA) at a
density of 12,000 cells per well and differentiation was started in the
presence or absence of 30 μM quinalizarin or 20 μM CX-4945 when
cells had reached conﬂuence. Every third day immunoﬂuorescence
analysis was performed as described [15]. For the identiﬁcation of
CK2αwe used themouse monoclonal antibody 1A5 [56], for the identiﬁ-
cation of CK2β the polyclonal rabbit serum#32 [16]. The PPARγ2 isoform
was detected with the anti-PPARγ2 antibody ab45036 (Abcam,
Cambridge, UK), the marker perilipin was identiﬁed with the speciﬁc
antibody D418 (Cell Signaling Technology, Schwalbach, Germany ). All
primary antibodies were incubated overnight.
2.5. Extraction of cells
Cells were washed twice with cold PBS, scraped off the plate,
centrifuged (250 ×g, 4 °C) and the pellet was extracted with RIPA-
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1% Triton X-100, 0.1% SDS, pH 8.0) in the presence of protease inhibitors
(CompleteTM, Roche Diagnostics, Mannheim, Germany). After 30 min on
ice cells were sonicated (3× 30 s). After lysing, the cell debris was
removed by centrifugation at 13,000 ×g. The protein content was
determined with the BioRad reagent dye (BioRad, Munich, Germany).
Protein extracts were immediately used for Western blot analysis or
for in vitro phosphorylation.
2.6. SDS-polyacrylamide gel electrophoresis and Western blot analysis
Proteins were analysed by SDS-polyacrylamide gel electrophoresis
according to the procedure of Laemmli [30]. 50 μg extracted proteins
were used for the analysis. Proteins dissolved in sample buffer
(130 mM Tris–HCl, pH 6.8, 0.02% bromophenol blue (w/v), 10%
β-mercaptoethanol, 20% glycerol (v/v), and 4% SDS) were separated
on a 12.5% SDS-polyacrylamide gel in electrophoresis buffer (25 mM
Tris–HCl, pH 8.8, 192 mM glycine, and 3.5 mM SDS) and transferred
onto a PVDF membrane (Roche Diagnostics, Mannheim, Germany) in
a buffer containing 20 mM Tris–HCl, 150 mM glycine, pH 8.3. The
membrane was blocked with 5% dry milk in PBS-Tween20 for 1 h and
then incubated with appropriate primary antibodies diluted in PBS–
Tween20 with 1% dry milk (incubation buffer). The membrane was
washed twice with the incubation buffer and incubated with the
peroxidase-coupled secondary antibody (anti-rabbit 1:30,000 or anti-
mouse 1:10,000 in incubation buffer) for 1 h. Signals were visualized
by the Lumilight system of Roche Diagnostics (Mannheim, Germany).
For the detection of protein kinase CK2 we used themouse monoclonal
antibodies 1A5 (α-subunit) [56] and 6D5 (β-subunit) [43]. GAPDHwas
detected with the speciﬁc antibody FL-335 (Santa Cruz Biotechnology,
Heidelberg, Germany) and perilipin with D418 (Cell Signaling
Technology, Schwalbach, Germany). All antibodies were diluted 1:1000
in the incubation buffer and incubated with the membrane for 1 h at
room temperature or overnight at 4 °C.
2.7. CK2 in vitro phosphorylation assay
To determine the kinase activity of CK2, cells were lysed and the
extracts were used in a kinase ﬁlter assay. In this assay we measured
the incorporation rate of [32P]phosphate into the synthetic CK2 speciﬁc
substrate peptide with the sequence RRRDDDSDDD [29]. Twenty
microlitre kinase buffer (50 mM Tris–HCl, pH 7.5, 100 mM NaCl,
10 mM MgCl2, 1 mM DTT) containing 20 μg proteins was mixed with
30 μl CK2 mix (25 mM Tris–HCl, pH 8.5, 150 mM NaCl, 5 mM MgCl2,
1 mM dithiothreitol (DTT), 50 μM ATP, 0.19 mM substrate peptide,
containing 10 μCi/500 μl [32P]γATP) and incubated at 37 °C for 10 min.
The mixture was spotted onto a P81 ion exchange paper. The paper was
washedwith 85mMH3PO4 for three times. After treatment with ethanol
the paper was dried and the Čerenkov-radiation was determined in a
scintillation counter.
2.8. MTT viability assay
Cell proliferation and viability was determined using a colorimetric
MTT-based assay (MTT: 3-[4, 5-dimethylthiazol-2-yl] 2, 5-diphenyl
tetrazolium bromide, Sigma-Aldrich, Deisenhofen, Germany) as
described in [54].
3. Results
3.1. CK2 expression, activity and localization during the adipogenic
differentiation of human mesenchymal stem cells
It is well known that the CK2 protein level, as well as the protein
kinase activity is elevated in cancer cells compared to normal cells.
Further, inhibition of the kinase activity in cancer cells results in apoptosiswhereas normal cells survive. These observations led to the conclusion
that CK2 has anti-apoptotic properties. There are some indications, that
CK2 also plays a role in the development of organs and in differentiation.
However, nothing is known about its role in the differentiation of stem
cells to adipocytes. As adult stem cells like hMSCs play an important
role in tissue maintenance or regeneration processes of injured tissue
we investigated the role of CK2 in proliferating and differentiating hMSCs.
Adipogenic differentiation was induced in hMSCs for 21 days while
theirmorphology and lipid storagewere veriﬁed by time lapse imaging.
During hMSC differentiation cell morphology changed from a ﬁbroblast-
like to a rounded shape and lipid droplet formation appeared from day
6 on and increased until day 21 (Fig. 1A).
We wondered whether this differentiation process might be
accompanied by alteration in the expression of CK2 or/and the protein
kinase activity. Therefore, proteins were extracted and subsequently
analysed by Western blot analysis for the detection of the catalytic
α- and regulatory β-subunits as well as an in vitro phosphorylation
assay with a CK2-speciﬁc substrate peptide at certain time points. We
observed a decrease of the expression of CK2α (Fig. 1B). The expression
of the regulatory β-subunit varied in the course of differentiation;
however, at the end the expression of the protein was down-regulated
to about 80% of the control. Thus, the expression of both subunits is
seemingly individually regulated during the differentiation process. The
reduction in the expression of the CK2α subunitwent alongwith a reduc-
tion in kinase activity (Fig. 1C). By the end of differentiation we noticed
only about half of the initial CK2 activity.
Beside the detection of lipid droplets in situ, we also analysed a
marker protein for differentiation by Western blot, namely perilipin,
a protein surrounding the lipid droplets. Perilipinwas ﬁrst detectable at
day 12 and its expression increased until the end of differentiation
(Fig. 1B).
In a next experiment we analysed the subcellular localization of
protein kinase CK2. The results of these immunoﬂuorescence studies
are shown in Fig. 2. We observed a predominant nuclear staining for
the catalytic α-subunit of CK2. Beginning from day 12 the localization
of the α-subunit became more and more cytoplasmic. The regulatory
β-subunit initially showed an overall staining which became more
and more nuclear during differentiation with the most intense nuclear
staining at days 6 and 9. Afterwards, the β-subunit was redistributed
again in the cytoplasm and nucleus. Thus, CK2, especially the non-
catalytic β-subunit showed a dynamic shuttling during the adipogenic
differentiation of hMSCs. We also performed an immunoﬂuorescence
analysis of the late marker protein perilipin (Fig. 2). Single cells
expressed this lipid droplet surrounding protein already at day 6, and
its expression was steadily increasing till the end of differentiation.
3.2. CK2 inhibitors CX-4945 and quinalizarin reduce CK2 activity in
non-differentiating human mesenchymal stem cells
Over the last few years CK2 has been discovered as therapeutic
target for the treatment of cancer and several CK2 inhibitors have
been developed which are tested in ongoing clinical trials [61,62].
Although some of the inhibitors – especially CX-4945 – show high
bio-availability, good pharmacokinetics and non-cardiac toxicity [64],
no one has yet tested the impact of CK2 inhibitors on the fate of adult
stem cells.
In order to study the inhibition of CK2 in human stem cells, we chose
thewell-accepted CK2 inhibitor quinalizarin [9] and as a second inhibitor
CX-4945, which is currently investigated in clinical phase II trials as a
tumour therapeutic drug [61]. As the inhibition of such an essential kinase
like CK2 might be fatal for the viability of cells, we ﬁrst tested different
concentrations of the inhibitors in a viability assay. We treated
proliferating hMSCs with different concentrations of both inhibitors
which formerly have been proven suitable for the treatment of
established cell lines in our laboratory. After 24, 48 and 72 hour incuba-
tion with the inhibitor we performed an MTT assay where the activity
Fig. 1. Lipid droplet formation, CK2 expression and CK2 activity in differentiating hMSCs. Time-lapse images of hMSCs are shown after induction of adipogenic differentiation (A). CK2α- and
β-subunits and perilipin in differentiating hMSCs shown byWestern blot analysiswith speciﬁc antibodies over time. GAPDHwas used as a loading control. One representative of threeWestern
blots is shown. Bands are quantiﬁed against GAPDH (B). CK2 activity [%] during adipogenic differentiation of hMSC over time shownby the incorporation of [32P]phosphate into the CK2 speciﬁc
peptide RRRDDDSDDD of at least three independent experiments with two technical replicates each (C).
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cells was calculated in reference to a control with the solvent DMSO. As
shown in Fig. 3A the relative viability of hMSC was only slightly affected
by the addition of 20, 30 or even 40 μMquinalizarin. In contrast, the appli-
cation of CX-4945 resulted in a drop of viability ranging from 70% viable
cells (20 μM, 24 h) to only 35% after 72 h (40 μM, 72 h). We asked next
whether these inhibitors were able to reduce CK2 activity in hMSCs.
Based on the results of the viability assay we used 30 μM quinalizarin
and 20 μM CX-4945. Cells were treated over 24, 48 and 72 h and
harvested, proteins were extracted and subjected to an in vitro kinase
assaywith the CK2-speciﬁc substrate peptide. CK2 activity was efﬁcientlyreduced to 10% residual activitywith 20 μMCX-4945 already after 24 h of
treatment; this reduction was not stronger after longer incubation times
(Fig. 3B). Similar results were observed with quinalizarin, where we
found a 25% residual activity already after 24 h, which did not decrease
further after longer incubation times (Fig. 3C).
3.3. CK2 inhibitors CX-4945 and quinalizarin have a different impact upon
the adipogenic differentiation of human mesenchymal stem cells
Next, we investigated the inﬂuence of CK2 inhibitors on hMSCs
during adipogenic differentiation. We incubated hMSCs with 20 μM
Fig. 2. Localization of the CK2 subunits during differentiation of hMSCs. Adipogenic differentiation was started when cells reached conﬂuence. Every three days cells were ﬁxed and
immunoﬂuorescencewasperformed. CK2αwas detectedwith themousemonoclonal antibody 1A5 and labelled byAlexa Fluor 546-coupled secondary antibody (red). CK2βwasdetected
with a rabbit polyclonal antibody and labelled by Alexa Fluor 488-coupled secondary antibody (green). Perilipin was used as a differentiation control, detected with a rabbit polyclonal
antibody and labelled by Alexa Fluor 488-coupled secondary antibody (green). The nucleus was stained with DAPI. One representative of two experiments is shown here.
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21 days. The state of adipogenic differentiation of inhibitor-treated cells
and control cells was evaluated by the appearance of lipid droplets
(Fig. 4A and B). In hMSCs treated with the solvent DMSO for control we
observed differentiating hMSCs already at day 9 and this population
increased further until day 21. After treatment of hMSCs with CX-4945
only single cells with a differentiated phenotype appeared at day 9, but
at day 15 the differentiating cell population was signiﬁcantly increased
and at day 21 cells were differentiated similar to the untreated controlcells. In contrast, cells treated with the CK2 inhibitor quinalizarin demon-
strated a completely other outcome. At day 9 a small number of cells
harbouring lipid droplets had formed, but this population did not increase
during the differentiation process. At the end of the differentiation period
most of the hMSCs remained undifferentiated. The difference between
the three differently treated cell populations was more impressively
shown by staining the lipid droplets at day 21 of the differentiation
process with the lipophilic dye OilRedO or with the ﬂuorescent dye
Bodipy® (Fig. 4B).
Fig. 3. Effect of different CK2 inhibitors on cell viability and CK2 activity in proliferating
hMSCs. hMSCs were grown under non-differentiating conditions and treated with different
concentrations of CX-4945 or quinalizarin. Cell viability was determined using the MTT
assay after 24, 48 and 72 h of incubation. Viability was set in reference to the solvent
DMSO. The mean and standard deviation of two independent experiments with two
technical replicates each are shown (A). To measure the CK2 activity hMSCs were either
treated with 20 μM CX-4945 (B) or 30 μM quinalizarin (C) or the vehicle DMSO as a
control. After 24, 48 and 72 h cells were harvested, extracted and subjected to an
in vitro phosphorylation with the CK2 speciﬁc peptide and [32P]γATP. The graph
shows the incorporation of [32P]phosphate into the peptide in counts per minute (cpm) of
three independent experiments with two technical replicates each.
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the CK2 activity in differentiating human mesenchymal stem cells
Although we have tested both CK2 inhibitors before starting the
differentiation process and demonstrated that CK2 kinase activity
was inhibited with great efﬁcacy in proliferating hMSCs we wondered
whether this inhibition activity is maintained during differentiation.
Therefore, we started the differentiation of hMSCs in the presence or in
the absence of CK2 inhibitors. After 24, 48 and 72 h we either performed
a viability assay or extracted the proteins and subjected the extract to an
in vitro phosphorylation of the CK2 speciﬁc substrate peptide. Fig. 5A
shows the outcome of the viability assay. As for proliferating hMSCs
(see Fig. 3A) quinalizarin had no great impact on the viability of differen-
tiating hMSCs. Viabilitywas hardly reduced to 90%. Concerning the effectsof CX-4945, differentiating hMSCs turned out to be less sensitive towards
the treatment than their proliferating counterparts (60% viable cells
vs. 35%). Next, we analysed the consequences of the treatment for the
cellular CK2 activity. Surprisingly, in cells treated with CX-4945 (20 μM)
the CK2 activity was only reduced to about 40% residual activity after
24 h (Fig. 5B). Moreover, the inhibition of CK2 enzyme activity by
CX-4945 decreased again slightly from 24 h to 72 h, to a residual activity
of 75% compared to control cells.
In contrast, using quinalizarin we observed a down-regulation
of CK2 activity to about 25% of the original activity after 24, 48 and
72 hour treatment which corresponded to an inhibiting activity of 75%
(Fig. 5C). This corresponded with the inhibiting effect we observed in
proliferating cells with quinalizarin. Obviously, both inhibitors differ in
their inhibition efﬁcacy towards CK2 in differentiating cells. The different
effect on CK2 activity correlates perfectly with the adipogenic differentia-
tion capacity of hMSC when treated with CX-4945 or quinalizarin. This
further supports the observation that the CK2 kinase activity is necessary
for the adipogenic differentiation process of human stem cells.
3.5. Localization of adipocyte marker proteins in differentiating hMSCs
The correct localization of key signal transduction proteins is a
prerequisite for a successful differentiation. A key transcription factor
during the early stage of adipogenic differentiation is PPARγ, in particular
the γ2 isoform [59]. PPARγ is a ligand activated, early stage transcription
factorwhich transactivates further key components leading to the expres-
sion of adipocyte speciﬁc proteins like the fatty acid binding protein
perilipin [39]. From previous experiments (Figs. 1 and 2) we know that
lipid droplets appear from day 6 of differentiation onwards. Moreover,
we suspect from the CK2 dynamics that an active participation of CK2 in
the differentiation takes place at early stages. Thus, we analysed PPARγ2
and perilipin localization until day 9 in the absence and presence of
CX-4945 or quinalizarin (Fig. 6). PPARγ2 showed a nuclear localization
at the beginning of differentiation.We observed amore intensive nuclear
staining when hMSCs proceeded in the adipogenic differentiation. The
fatty acid binding protein perilipin was ﬁrst seen at day 6 and its expres-
sion steadily increased. Using CX-4945 as inhibitor essentially led to the
same results as the control cells with a little delay in the ﬁrst appearance
of perilipin (day 9 vs. day 6). However, this observation coincided with
the delay in the formation of lipid droplets after CX-4945 treatment
(Fig. 4A). When analysing the proteins in quinalizarin treated cells we
observed a somewhat different outcome. As for the control cells PPARγ2
was ﬁrst present in the nuclear compartment. During the course of
treatment PPARγ2 was not able to increase or maintain the nuclear
localization; it became more and more cytoplasmic. In consequence, the
expression of the PPARγ2 target perilipin was missing in the quinalizarin
treated cells. Thus, upon CK2 inhibition the nuclear translocation of
a master transcription factor of adipogenesis is abrogated and
consequently, all downstream events are therefore interrupted.
4. Discussion
It is known for quite some time that protein kinase CK2 is absolutely
necessary for the correct development of organisms and that life without
CK2α and/or CK2β is impossible [5,35]. On the other hand, the level and
the protein kinase activity are elevated in rapidly proliferating cells [18,
42]. The proliferation promoting activity might also be responsible for
cell death in the developing embryo of CK2α knock-out mice. Further-
more, the importance of CK2 for cell growth is supported by the observa-
tion that a great number of CK2 substrates are implicated in the regulation
of proliferation and growth [37]. Moreover, overexpression of CK2α and
c-myc resulted in the formation of leukaemia in mice which supports
the idea that at least CK2α might have oncogenic properties [32,58].
These observations have brought CK2 into the focus as a therapeutic
target for the treatment of human cancer. A great number of CK2
inhibitors have been developed over the last ten years and at least
Fig. 4.Adipogenic differentiation of hMSC in the presence or absence of CK2 inhibitors. hMSCswere seeded into six-well plates, induced to differentiate in the presence or absence of 20 μM
CX-4945 or 30 μMquinalizarin.(A). Brightﬁeld images show the lipid droplet formation at days 0, 9, 15 and 21 (B). At day 21 lipid droplets in adipogenically differentiated hMSCs were either
stainedwithOilRedO and analysed by phase contrastmicroscopy or stainedwith the lipophilicﬂuorescent dye Bodipy® and analysed under aﬂuorescencemicroscope (excitationwave length:
488 nm).
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4945 which has been shown to have anti-angiogenic, anti-proliferative
and apoptosis-inducing properties in cancer cells. Apart from its involve-
ment in proliferation there are reports showing that CK2might also play arole in the regulation of the carbohydratemetabolism, in regulation of the
insulin production in β-cells of the pancreas [38], in information storage,
synaptic plasticity, synaptic transmission and development of the brain
[2] and also during differentiation [63,72].
Fig. 5. Effect of CK2 inhibitors on cell viability and CK2 activity in differentiating hMSCs.
ConﬂuenthMSCswere incubatedwith thedifferentiationmix including given concentrations
of CX-4945, quinalizarin or DMSO as control. Cell viability was determined using the MTT
assay after 24, 48 and 72 h of incubation. Viability was set in reference with DMSO.
The mean and standard deviation of three independent experiments with two technical
replicates each are shown (A). To measure the CK2 activity differentiation was started
with the differentiation mix and 20 μM CX-4945 (B), 30 μM quinalizarin (C) or with
DMSO for control. After 24, 48 and 72 h cells were harvested, extracted and subjected to
an in vitro phosphorylation with the CK2 speciﬁc peptide and [32P]γATP. The graph
shows the incorporation of [32P]phosphate into the peptide in counts per minute (cpm)
of three independent experiments with two technical replicates each.
2214 L. Schwind et al. / Biochimica et Biophysica Acta 1853 (2015) 2207–2216Recently, it was found that inhibition of the kinase activity of CK2 by
CX-4945 leads to an inhibition of osteoclast and osteoblast differentiation
[63]. In line with this observation it was reported in 2012 that CK2 is
implicated in the differentiation of preadipocytes into adipocytes in the
mouse cell line 3T3-L1 [72]. In the present study we could show for the
ﬁrst time that CK2 plays a role in the differentiation of human stem
cells. Upon progression of the differentiation the level of CK2α and
CK2βdecreased. Surprisingly, the expression of theα- and theβ-subunits
was not evenly down-regulated. The down-regulation of the α-subunit
was more signiﬁcant than that of the β-subunit (56 vs. 83%). This result
is one of the few examples that the subunits have to be considered as
individual proteins with distinct functions and a distinct regulation. The
decrease in expression was accompanied by a reduction of the protein
kinase activity of CK2 which was also seen during the differentiation
process of preadipocytes. Another interesting observation was thatCK2α andCK2βobviously localize independently to thenucleus.Whereas
CK2α showed amostly nuclear staining, the CK2β subunit represents the
more dynamic component of the holoenzyme. It shuttles from the cyto-
plasm to the nucleus to presumably form an active holoenzyme with
the α-subunit. Although, there are few examples that the α-subunit can
phosphorylate substrates without its regulatory subunit, most substrates
are phosphorylated by the holoenzyme [48]. It is known for tagged CK2
subunits that they undergo a dynamic shuttling and that they enter the
nucleus independently [17]. In a recent paper we observed in glucose
responsive MIN6 cells a glucose dependent shuttling of CK2 from the
cytoplasm into the nucleus [71]. Here, we add another example where
endogenous CK2 shows a spatial re-organization during a physiological
process.
Quinalizarin was tested with 72 kinases and CX-4945 was tested
with 235 kinases and both turned out to be highly CK2 speciﬁc [1,9].
Using quinalizarin and CX-4945 in proliferating human stem cells we
observed an efﬁcient inhibition of the CK2 kinase activity. Although it
has been repeatedly observed that every inhibitor has to be tested on
a particular cell line and that there are enormous differences in the
efﬁciency of inhibition, the general observation is that CX-4945 is
more active than quinalizarin. Also in the present study CX-4945 was
more active at lower concentrations than quinalizarin. From the results
published so far it also seems that normal non-cancer cells require
higher concentrations of CX-4945 than cancer cells to inhibit CK2 [74].
Moreover, normal cell lines seem to be somewhat more resistant
towards the anti-proliferative efﬁcacy of CK2 inhibitors [25]. Using
quinalizarin as CK2 inhibitor only a few hMSCs differentiate to an
adipogenic phenotype. In contrast, CX-4945 treated cells differentiate
very efﬁciently similar to the control cells. However, the differentiation
in CX-4945 treated cells is retarded in the initial phase. The analysis of
the reason for this discrepancy reveals that the inhibition of the CK2
activity decreases during the differentiation process of stem cells in the
case of CX-4945 whereas inhibition of CK2 remains high in the presence
of quinalizarin. These results show that the remaining CK2 activity in
the presence of CX-4945 is sufﬁcient for adipogenic differentiation of
human stem cells, whereas the low activity of CK2 in the presence of
quinalizarin is not. Thus, a particular threshold of CK2 kinase activity
seems to be required for the adipogenic differentiation of human stem
cells. The reason for the failure of CX-4945 to ensure a permanent
inhibition of CK2 in these stems cells during differentiation remains
to be elucidated. Even higher concentrations of CX-4945 (30 and 40 μM)
failed to reduce the kinase activity efﬁciently (data not shown). It is
tempting to speculate that hMSC, which share similarities with cancer
cells, develop some kind of drug resistance in response to the CX-4945
treatment as it is known for tumour cells [67,69].
Our present data show that CK2 plays a role in the early phase of
differentiation. CK2 activity, expression and localization are necessary
for the timely activation of themaster transcription factor for adipogen-
esis, PPARγ2. We know from a recently published paper [57] that the
upstream transcription factor C/EBPδ is a substrate for CK2, and that
its transactivation efﬁciency is inﬂuenced by CK2 phosphorylation.
Furthermore, we have shown that the localization of the C/EBPδ down-
stream target PPARγ2 changes during differentiation and that its nuclear
localization is compromised upon CK2 inhibition. Whether this is due to
an indirect impact of CK2 via C/EBPδ or a direct impact of the kinase on
PPARγ2 remains to be elucidated.
Although in most cases CK2 has to be down-regulated during
differentiation, a particular threshold of CK2 activity is required for the
adipogenic differentiation of human stem cells.5. Conclusion
CK2 activity is high at the beginning of stem cell differentiation.
With the progress of differentiation CK2 activity and protein level are
down-regulated. Experiments with CK2 inhibitors show that a particular
Fig. 6. Localization of PPARγ2 during differentiation of hMSC in the presence and absence of CX-4945 or quinalizarin. When cells reached conﬂuence differentiation mix including 20 μM
CX-4945, 30 μMquinalizarin or DMSO as solvent control was added to start adipogenic differentiation. At given time points cells were ﬁxed and immunoﬂuorescence was performed. PPARγ2
was detected with a rabbit polyclonal antibody and labelled by Alexa Fluor 488-coupled secondary antibody (green). Perilipin was used as a differentiation control, detected with a rabbit
polyclonal antibody and labelled by Alexa Fluor 488-coupled secondary antibody (green). The nucleus was stained with DAPI. One representative of two experiments is shown here.
2215L. Schwind et al. / Biochimica et Biophysica Acta 1853 (2015) 2207–2216threshold of CK2 activity is required for a successful adipogenic
differentiation of stem cells.
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